Acute Graft Versus Host Disease Clinical Trial
Official title:
Clinical Trial Phase I / II Graft Versus Host Disease Treatment Refractory to First-line Therapy With Sequential Infusion of Mesenchymal Cells Allogeneic Expanded Adipose Tissue in Vitro
Sequential administration of MSCs obtained from adipose tissue is an effective and safe treatment for acute graft versus host disease refractory to first-line treatment. Furthermore the infusion of these cells produces a biological pattern in patients that relates to the clinical response.
Multicenter, open, non -controlled clinical trial. It is a phase I-II trial to assess the safety and efficacy of sequential infusion of allogeneic MSCs from adipose tissue, expanded "in vitro" platelet lysate in the treatment of patients undergoing hematopoietic stem cell trasplantation, who have developed a refractory graft versus host disease to first line of treatment. This is a prospective, multicenter, open to patients undergoing allogeneic transplantation in Spanish hospitals, with one cohort of patients who receive four sequential doses of MSC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01140984 -
Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD)
|
N/A | |
| Completed |
NCT00803010 -
Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 2 | |
| Withdrawn |
NCT04280471 -
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
|
Phase 1 | |
| Withdrawn |
NCT02425813 -
Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract
|
Phase 2 | |
| Terminated |
NCT00038792 -
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD
|
Phase 1/Phase 2 | |
| Terminated |
NCT04521777 -
Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy
|
N/A | |
| Terminated |
NCT02436460 -
A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant
|
Phase 1 | |
| Not yet recruiting |
NCT01596192 -
PETCT for Diagnosing and Monitoring Acute GVHD
|
N/A | |
| Completed |
NCT00726375 -
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
|
Phase 3 | |
| Recruiting |
NCT05823675 -
Safety and Clinical Activity of Itolizumab in aGVHD
|
Phase 1 | |
| Not yet recruiting |
NCT06386445 -
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
|
||
| Recruiting |
NCT05443425 -
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT03158896 -
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
|
Phase 1 | |
| Not yet recruiting |
NCT06444022 -
hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
|
Early Phase 1 | |
| Active, not recruiting |
NCT04976699 -
CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
|
Phase 3 | |
| Terminated |
NCT04095858 -
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
|
Phase 3 | |
| Terminated |
NCT00032773 -
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
|
Phase 1/Phase 2 | |
| Completed |
NCT02359929 -
BMT Autologous MSCs for GvHD
|
Phase 1 | |
| Withdrawn |
NCT00640497 -
Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT03491215 -
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
|
Phase 1/Phase 2 |